TrialThe Journal of infectious diseases2026
Safety, Pharmacokinetics, and Pharmacodynamics of Single-Dose Programmed Cell Death Protein 1 Inhibitor, Budigalimab, in People With HIV-1 With Antiretroviral Therapy-Suppressed Viral Load.
Tanaya R Vaidya et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.